Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases

Shared on01 May 25
Fair value Decreased 9.39%

Shared on24 Apr 25
Fair value Increased 10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 9.40%

Shared on09 Apr 25
Fair value Increased 18%

AnalystConsensusTarget has increased future PE multiple from 397.2x to 472.3x.

Shared on02 Apr 25
Fair value Decreased 17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.